[1] CERBELLI B,PERNAZZA A,BOTTICELLI A,et al.PD-L1 expression in TNBC:A predictive biomarker of response to neoadjuvant chemotherapy?[J].Biomed Res Int,2017(2017):1750925. [2] CUI X,SONG D,LI X.Construction and validation of nomograms predicting survival in triple-negative breast cancer patients of childbearing age[J].Front Oncol,2021(10):636549. [3] CUI X,ZHU H,HUANG J.Nomogram for predicting lymph node involvement in triple-negative breast cancer[J].Front Oncol,2020(10):608334. [4] XIN Y,SHEN G,ZHENG Y,et al.Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer:A systematic review and meta-analysis[J].BMC Cancer,2021,21(1):1261. [5] LIN Y Y,GAO H F,YANG X,et al.Neoadjuvant therapy in triple-negative breast cancer:A systematic review and network meta-analysis[J].Breast,2022(66):126-135. [6] 叶晔,费伟强,冯冠.SEER数据库中晚期三阴性乳腺癌的危险因素及预后分析[J].广州医药,2021,52(1):26-34. [7] GUHA A,FRADLEY M G,DENT S F,et al.Incidence,risk factors,and mortality of atrial fibrillation in breast cancer:A SEER-Medicare analysis[J].Eur Heart J,2022,43(4):300-312. [8] 曲南坤,梁爽,孔启超,等.基于SEER数据库建立三阴性乳腺癌预后预测模型列线图[J].重庆医学,2021,50(20):3457-3462,3468. [9] 黄雅静,吴昊,陈彦,等.基于SEER数据库的炎性乳腺癌生存预测风险模型的建立与验证[J].现代肿瘤医学,2022,30(6):1023-1027. [10] 来保勇,吕灵艳,赵静,等.10种口服中成药联合化疗治疗乳腺癌的网状Meta分析[J].中草药,2021,52(21):6609-6624. [11] 殷雨来,李雪,何晓阳,等.体质量指数和4种女性特征性癌症的因果关系:一项两样本孟德尔随机化研究[J].中华肥胖与代谢病电子杂志,2023,9(4):253-260. [12] 许关麟,李建文,黄胜超,等.那不勒斯评分预测乳腺癌患者预后的价值[J].现代医院,2024,24(1):53-58. [13] 颜娇,叶入裴,杨琴,等.不同亚型乳腺癌新辅助化疗后Ki-67表达变化与乳腺癌疗效及预后的相关性[J].诊断病理学杂志,2022,29(11):1001-1004. [14] HUANG X,LUO Z,LIANG W,et al.Survival nomogram for young breast cancer patients based on the SEER database and an external validation cohort[J].Ann Surg Oncol,2022,29(9):5772-5781. [15] FAN Y,WANG Y,HE L,et al.Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival[J].ESMO Open,2021,6(4):100232. [16] XIA L Y,XU W Y,ZHAO Y.Effect of postmastectomy radiotherapy on T1-2N1M0 triple-negative breast cancer[J].PLoS One,2022,17(6):e0270528. [17] ANDREOU C,MATSAKAS A.Current insights into cellular senescence and myotoxicity induced by doxorubicin:The role of exercise and growth factors[J].Int J Sports Med,2022,43(13):1084-1096. [18] WU B B,LEUNG K T,POON E N.Mitochondrial-targeted therapy for doxorubicin-induced cardiotoxicity[J].Int J Mol Sci,2022,23(3):1912. [19] SZMIT S,FILIPIAK K J,LITWINIUK M,et al.Liposomal doxorubicin in patients with breast cancer and concomitant cardiovascular diseases - interdisciplinary expert opinion[J].Kardiol Pol,2016,74(9):1031-1036. [20] MIN Y,LIU X,HU D,et al.Risk factors,prognostic factors,and nomogram for distant metastasis in breast cancer patients without lymph node metastasis[J].Front Endocrinol(Lausanne),2021(12):771226. [21] RIZZO A,CUSMAI A,ACQUAFREDDA S,et al.KEYNOTE-522,IMpassion031 and GeparNUEVO:Changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer[J].Future Oncol,2022,18(18):2301-2309. [22] SCHMID P,CORTES J,DENT R.Pembrolizumab in early triple-negative breast cancer[J].N Engl J Med,2022,386(18):1771-1772. [23] CHEN F,CHEN N,GAO Y,et al.Clinical progress of PD-1/L1 inhibitors in breast cancer immunotherapy[J].Front Oncol,2022(11):724424. [24] HAN Y,LIU D,LI L.PD-1/PD-L1 pathway:Current researches in cancer[J].Am J Cancer,2020,10(3):727-742. [25] WU S Y,XU Y,CHEN L,et al.Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC:Concept exploration and biomarker analysis in the FUTURE-C-Plus trial[J].Mol Cancer,2022,21(1):84. |